During a live event, Matthew Galsky, MD discussed neoadjuvant and adjuvant options for a patient case including nivolumab or dose-dense MVAC.

A post-hoc analysis of the DUPLEX trial shows significantly greater improvements in proteinuria-related outcomes vs irbesartan for tough-to-treat FSGS.

In less than a decade, the global contracting and consulting firm Jacobs Solutions changed names, moved cities, and shifted ...

Puma Biotechnology offers runway stability but lacks clear growth drivers amid drug headwinds and pipeline gaps. Find out why ...

The table below is a review of notable updates that occurred in March 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

SNS Insider Forecasts 13.29% CAGR from 2024 to 2032 as Demand Surges Across Pharma, Genomics, and AgricultureAustin, April 11, 2025 (GLOBE NEWSWIRE) -- Global Biotechnology Market Size & Growth ...